Health care stocks were mixed premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) was down a slight 0.2% and the iShares Biotechnology ETF (IBB) was recently inactive.
Humana (HUM) shares rose nearly 3% after the company reported an increase in Q4 revenue and issued a 2025 revenue outlook above analysts' expectations.
Biohaven (BHVN) shares advanced by over 7% after the company said the Food and Drug Administration accepted for priority review its new drug application for troriluzole to treat adult patients with spinocerebellar ataxia.
Royalty Pharma (RPRX) shares were down more than 0.4% after the company reported lower Q4 net income and revenue.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。